With “superbugs” stalking hospitals and old killers such as tuberculosis re-emerging, the world badly needs more powerful antibiotics. Yet the pipeline of new treatments is drying up as drug firms -- citing poor financial returns -- focus instead on chronic conditions, such as high cholesterol, where medicines are taken for years rather than curing patients in one or two weeks.
